Early Remdesivir for Patients Who Are Immunocompromised and Hospitalized With COVID-19
Abstract Background Patients who were immunocompromised were largely excluded from COVID-19 clinical trials, and real-world evidence on remdesivir effectiveness has produced conflicting results. We evaluated whether early remdesivir initiation (vs late or never) reduces in-hospital mortality among patients who are immu...